Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A. Fundamental Analysis
Newron Pharmaceuticals S.p.A. (NWPHF) shows moderate financial fundamentals with a PE ratio of 8.00, profit margin of 47.03%, and ROE of 16.69%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 49.8/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze NWPHF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentNWPHF demonstrates superior asset utilization.
Valuation Score
ExcellentNWPHF trades at attractive valuation levels.
Growth Score
WeakNWPHF faces weak or negative growth trends.
Financial Health Score
ModerateNWPHF shows balanced financial health with some risks.
Profitability Score
ExcellentNWPHF achieves industry-leading margins.
Key Financial Metrics
Is NWPHF Expensive or Cheap?
P/E Ratio
NWPHF trades at 8.00 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, NWPHF's PEG of 0.16 indicates potential undervaluation.
Price to Book
The market values Newron Pharmaceuticals S.p.A. at 128.24 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 5.17 times EBITDA. This is generally considered low.
How Well Does NWPHF Make Money?
Net Profit Margin
For every $100 in sales, Newron Pharmaceuticals S.p.A. keeps $47.03 as profit after all expenses.
Operating Margin
Core operations generate 64.02 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $16.69 in profit for every $100 of shareholder equity.
ROA
Newron Pharmaceuticals S.p.A. generates $41.31 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Newron Pharmaceuticals S.p.A. produces operating cash flow of $7.89M, showing steady but balanced cash generation.
Free Cash Flow
Newron Pharmaceuticals S.p.A. generates strong free cash flow of $7.87M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.39 in free cash annually.
FCF Yield
NWPHF converts 3.88% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
8.00
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.16
vs 25 benchmark
P/B Ratio
Price to book value ratio
128.24
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.76
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
33.23
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.51
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
16.69
vs 25 benchmark
ROA
Return on assets percentage
0.41
vs 25 benchmark
ROCE
Return on capital employed
1.62
vs 25 benchmark
How NWPHF Stacks Against Its Sector Peers
| Metric | NWPHF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 8.00 | 29.45 | Better (Cheaper) |
| ROE | 1668.65% | 779.00% | Excellent |
| Net Margin | 47.03% | -24936.00% (disorted) | Strong |
| Debt/Equity | 33.23 | 0.26 | Weak (High Leverage) |
| Current Ratio | 1.51 | 4.65 | Neutral |
| ROA | 41.31% | -19344.00% (disorted) | Strong |
NWPHF outperforms its industry in 4 out of 6 key metrics, particularly excelling in ROE, but lagging in Debt/Equity.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Newron Pharmaceuticals S.p.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation